102 related articles for article (PubMed ID: 27035428)
1. Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.
Domińska K; Ochędalski T; Kowalska K; Matysiak-Burzyńska ZE; Płuciennik E; Piastowska-Ciesielska AW
Int J Oncol; 2016 Jun; 48(6):2619-28. PubMed ID: 27035428
[TBL] [Abstract][Full Text] [Related]
2. A common effect of angiotensin II and relaxin 2 on the PNT1A normal prostate epithelial cell line.
Domińska K; Ochędalski T; Kowalska K; Matysiak-Burzyńska ZE; Płuciennik E; Piastowska-Ciesielska AW
J Physiol Biochem; 2016 Sep; 72(3):381-92. PubMed ID: 27119161
[TBL] [Abstract][Full Text] [Related]
3. Regulation of mRNA gene expression of members of the NF-κB transcription factor gene family by angiotensin II and relaxin 2 in normal and cancer prostate cell lines.
Domińska K; Kowalska K; Matysiak ZE; Płuciennik E; Ochędalski T; Piastowska-Ciesielska AW
Mol Med Rep; 2017 Jun; 15(6):4352-4359. PubMed ID: 28487955
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Ang-(1-9) and Ang-(3-7) on the Biological Properties of Prostate Cancer Cells by Modulation of Inflammatory and Steroidogenesis Pathway Genes.
Domińska K; Kowalska K; Urbanek KA; Habrowska-Górczyńska DE; Ochędalski T; Piastowska Ciesielska AW
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872192
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.
Vinall RL; Mahaffey CM; Davis RR; Luo Z; Gandour-Edwards R; Ghosh PM; Tepper CG; de Vere White RW
Horm Cancer; 2011 Aug; 2(4):224-38. PubMed ID: 21789713
[TBL] [Abstract][Full Text] [Related]
6. Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells.
Bialek J; Kunanuvat U; Hombach-Klonisch S; Spens A; Stetefeld J; Sunley K; Lippert D; Wilkins JA; Hoang-Vu C; Klonisch T
Mol Cancer Res; 2011 Jun; 9(6):673-87. PubMed ID: 21493587
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation.
Domińska K; Piastowska-Ciesielska AW; Lachowicz-Ochędalska A; Ochędalski T
Peptides; 2012 Oct; 37(2):200-6. PubMed ID: 22884921
[TBL] [Abstract][Full Text] [Related]
8. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
9. Relaxin promotes prostate cancer progression.
Feng S; Agoulnik IU; Bogatcheva NV; Kamat AA; Kwabi-Addo B; Li R; Ayala G; Ittmann MM; Agoulnik AI
Clin Cancer Res; 2007 Mar; 13(6):1695-702. PubMed ID: 17363522
[TBL] [Abstract][Full Text] [Related]
10. Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A; Summerlee AJ; Silvertown JD
Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
[TBL] [Abstract][Full Text] [Related]
11. RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance.
Ma J; Huang H; Han Z; Zhu C; Yue B
Biomed Res Int; 2015; 2015():147468. PubMed ID: 26229955
[TBL] [Abstract][Full Text] [Related]
12. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.
Chen Y; Zheng L; Liu J; Zhou Z; Cao X; Lv X; Chen F
Int Immunopharmacol; 2014 Aug; 21(2):447-55. PubMed ID: 24905636
[TBL] [Abstract][Full Text] [Related]
13. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.
Chow L; Rezmann L; Imamura K; Wang L; Catt K; Tikellis C; Louis WJ; Frauman AG; Louis SN
Prostate; 2008 May; 68(6):651-60. PubMed ID: 18288685
[TBL] [Abstract][Full Text] [Related]
14. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Liu H; Chen A; Guo F; Yuan L
Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
[TBL] [Abstract][Full Text] [Related]
15. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Thompson VC; Hurtado-Coll A; Turbin D; Fazli L; Lehman ML; Gleave ME; Nelson CC
Prostate; 2010 Jul; 70(10):1134-45. PubMed ID: 20503398
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer.
Tevz G; McGrath S; Demeter R; Magrini V; Jeet V; Rockstroh A; McPherson S; Lai J; Bartonicek N; An J; Batra J; Dinger ME; Lehman ML; Williams ED; Nelson CC
Mol Cell Endocrinol; 2016 Jan; 420():159-68. PubMed ID: 26499396
[TBL] [Abstract][Full Text] [Related]
18. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.
Thompson VC; Morris TG; Cochrane DR; Cavanagh J; Wafa LA; Hamilton T; Wang S; Fazli L; Gleave ME; Nelson CC
Prostate; 2006 Dec; 66(16):1698-709. PubMed ID: 16998820
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effects of Angiotensin IV on androgen-dependent and androgen-independent prostate cancer cell lines.
Dominska K; Piastowska-Ciesielska AW; Pluciennik E; Lachowicz-Ochedalska A; Ochedalski T
J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):74-81. PubMed ID: 22679277
[TBL] [Abstract][Full Text] [Related]
20. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
Xiao LJ; Lin P; Lin F; Liu X; Qin W; Zou HF; Guo L; Liu W; Wang SJ; Yu XG
Int J Oncol; 2012 May; 40(5):1714-24. PubMed ID: 22200661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
